Nasdaq:US$15.97 (-0.33) | HKEX:HK$25.45 (-0.20) | AIM:£2.35 (+0)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors